Skip to main content
Equibles

ASND · Ascendis Pharma A/S · Financials

Track ASND — free

Use ASND with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ASND.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$234.33 +4.38 (+1.90%) At close · Oct 20
Russell 1000 member Rebalance outlook locked
Market Cap
$15.39B
Shares
65.80M
Volume · Oct 20 394.83K Avg daily vol (3M) 686.74K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Revenue
720.13M +98%
FY2025 Revenue FY2015–FY2025
Net Income
-228.03M +39.7%
FY2025 Net Income FY2018–FY2025
Gross Margin
86.82% -1pp
FY2025 Gross Margin FY2019–FY2025
Operating Margin
-18.92% +57.7pp
FY2025 Operating Margin FY2015–FY2025
Diluted EPS
-3.76 +42.4%
FY2025 Diluted EPS FY2015–FY2025
Operating Cash Flow
53.9M +117.6%
FY2025 Operating Cash Flow FY2015–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015
EUR 720.13M 363.64M 266.72M 51.17M 7.78M 6.95M 13.38M 10.58M 1.53M 4.61M 8.12M
EUR 94.92M 44.26M 44.4M 12.14M 3.52M 0 0 — — — —
EUR 625.22M 319.38M 222.32M 39.04M 4.26M 6.95M 13.38M — — — —
EUR 303.62M 307M 413.45M 379.62M 295.87M 260.9M 191.62M 140.28M 99.59M 66.02M 40.53M
EUR 17.21M 17.25M 18.43M 17.51M 14.95M 9.45M 6.69M 880K 734K 677K 558K
EUR -136.27M -278.76M -455.54M -561.81M -451.79M -330.62M -226.72M -154.76M -111.54M -72.92M -41.83M
EUR 206.69M 100.03M 44.07M 50.49M 3.91M 80.84M 1.22M 127K 13.76M 3.11M 2.8M
EUR -212.65M -373.24M -474.14M -577.82M -383.94M -419.17M -218.25M -130.49M -124.37M -68.73M -33.57M
EUR 15.38M 4.84M 7.3M 5.38M -367K -219K -234K -394K -477K -227K -652K
EUR -228.03M -378.08M -481.45M -583.19M -383.58M -418.96M -218.02M -130.1M -123.9M -68.51M -32.92M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2025: 144.31M in buybacks.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Noncurrent long-term borrowings 2026-06-30 EUR 384,642,000 6-K filed 2026-08-13
Short-term borrowings 2026-06-30 EUR 0 6-K filed 2026-08-13
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1612042 CUSIP K08588103 13F (30d) 25 filings 25 filers Visit website Investor relations